Algert Global LLC lifted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 50.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,742,942 shares of the company's stock after buying an additional 585,984 shares during the quarter. Algert Global LLC owned about 0.96% of Xeris Biopharma worth $13,804,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Xeris Biopharma during the second quarter valued at about $115,042,000. UBS Group AG boosted its position in shares of Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company's stock worth $14,511,000 after purchasing an additional 1,554,869 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company's stock valued at $87,815,000 after buying an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd grew its stake in shares of Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company's stock valued at $14,429,000 after buying an additional 1,245,188 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after buying an additional 1,199,435 shares in the last quarter. Institutional investors own 42.75% of the company's stock.
Analyst Ratings Changes
XERS has been the subject of several recent research reports. Barclays boosted their price objective on Xeris Biopharma from $9.00 to $12.00 and gave the company an "overweight" rating in a report on Thursday, August 20th. Weiss Ratings cut Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Xeris Biopharma currently has an average rating of "Hold" and a consensus target price of $12.00.
View Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Stock Performance
Shares of Xeris Biopharma stock opened at $8.74 on Wednesday. The company has a market capitalization of $1.59 billion, a P/E ratio of -79.45 and a beta of 0.66. The stock has a fifty day simple moving average of $8.19 and a 200 day simple moving average of $6.89. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Xeris Biopharma news, Director John Johnson sold 15,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $91,350.00. Following the completion of the sale, the director owned 683,083 shares in the company, valued at approximately $4,159,975.47. This trade represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the transaction, the director directly owned 126,500 shares in the company, valued at approximately $770,385. This represents a 11.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 271,499 shares of company stock worth $2,038,917 in the last ninety days. 4.35% of the stock is owned by corporate insiders.
Xeris Biopharma Company Profile
(
Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
